INIFY LABORATORIES AB Total Liabilities
INIFY LABORATORIES AB total liabilities. Based on the latest financial reports, INIFY LABORATORIES AB (WY60) has total liabilities worth €23.00 Million EUR (≈ $26.89 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of INIFY LABORATORIES AB to measure how many days the company can operate on defensive assets alone.
Total Liabilities of INIFY LABORATORIES AB (2021–2025)
Total liabilities of INIFY LABORATORIES AB from 2021 to 2025. This chart illustrates how INIFY LABORATORIES AB's total liabilities have evolved over time, based on quarterly financial data.
INIFY LABORATORIES AB Competitors by Total Liabilities
The table below lists competitors of INIFY LABORATORIES AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Landis Taipei Hotel Co Ltd
TWO:5703
|
Taiwan | NT$447.11 Million |
|
Ecoplastic Corporation
KQ:038110
|
Korea | ₩1.47 Trillion |
|
Leading Edge Materials Corp
V:LEM
|
Canada | CA$6.14 Million |
|
Metrod Holdings Bhd
KLSE:6149
|
Malaysia | RM1.57 Billion |
|
Valor Energy Inc.
NASDAQ:VAI
|
USA | $50.10 Million |
|
Qingdao Hengshun Zhongsheng
SHE:300208
|
China | CN¥2.41 Billion |
|
Unlu Yatirim Holding AS
IS:UNLU
|
Turkey | TL2.35 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down INIFY LABORATORIES AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is INIFY LABORATORIES AB's balance sheet.
Liquidity & Leverage Metrics
INIFY LABORATORIES AB Total Liabilities Ratios Explained
INIFY LABORATORIES AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how INIFY LABORATORIES AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for INIFY LABORATORIES AB (2021–2025)
The table below shows the annual total liabilities of INIFY LABORATORIES AB from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €34.02 Million ≈ $39.77 Million |
+258.09% |
| 2024-12-31 | €9.50 Million ≈ $11.11 Million |
+19.42% |
| 2023-12-31 | €7.95 Million ≈ $9.30 Million |
-42.18% |
| 2022-12-31 | €13.76 Million ≈ $16.08 Million |
-- |
| 2021-12-31 | €0.00 ≈ $0.00 |
-- |
About INIFY LABORATORIES AB
INIFY Laboratories AB provides cancer diagnostics services in Sweden. It offers prostate cancer diagnostics services. The company was incorporated in 2021 and is based in Stockholm, Sweden.